Fangcang shelter hospital research shows that Zhengqi tablets can significantly shorten the time for nucleic acid to turn negative for asymptomatic infections of the new crown

The "Prospective Real-World Cohort Control Study of Zhengqi Tablets in the Treatment of Mild and Asymptomatic Infections of Novel Coronavirus" led by Professor Gao Yueqiu, Vice President of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Captain of the TCM Medical Team at the Isolation Point, was completed in China After the clinical trial registration (registration number: ChiCTR2200058693) and the ethics approval of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (approval number: 2022-1099-36-01), the case admission and treatment was started at the Shanghai Urban Footprint Museum Fangcang shelter hospital on AprilEnrolled and completed the clinical trial on April 2

Recently, the research group held a clinical summary meeting, chaired by Academician Lin Guoqiang of the Chinese Academy of Sciences, and Professor Gao Yueqiu reported the implementation of the project and the research resul.

The results showed that Zhengqi Tablets could improve the nucleic acid negative conversion rate, and a good nucleic acid negative conversion effect could be seen within 2 days; the average negative conversion time after one course of treatment was 66 days, which was 56 days shorter than that of the control gro.

Professor Gao Yueqiu believes that taking Zhengqi Tablets shortens the time of nucleic acid turning negative for patients with mild and asymptomatic infections, which is of great significance in shortening the time for patients to be cured and leaving the cabin, reducing the diagnosis rate, and effectively reducing the treatment pressure of new crown patien.

Zhengqi Tablet is derived from Huoxiang Zhengqi Fang in the "Taiping Huimin Heji Jufang" in the Song Dynas.